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Abstract
Introduction: Several observations have suggested that the secretion of neurohypophysial hormones could be modified by gonadotro-
pin-releasing hormone (GnRH). Since, in medical practice, more often than GnRH itself, its analogues are used, the present study was 
undertaken to investigate the influence of the GnRH agonist — triptorelin on oxytocin (OT) and vasopressin (AVP) release from the rat 
hypothalamo-neurohypophysial (H-N) system both in vitro and in vivo.
Materials and methods: Male rats served as donors of the H-N explants, which were placed in 1 mL of Krebs-Ringer fluid (nKRF) and 
incubated successively in: 1 — nKRF (B1); 2 — incubation fluid as B1 enriched with an excess amount (56 mM) of K+ (S1); 3 — incubation 
fluid as B1 enriched with an appropriate concentration of triptorelin, i.e., 10–11 — 10–5 M (B2); and 4 — incubation fluid as S1 enriched with 
the same concentrations of triptorelin (S2). After 20 minutes of incubation, each medium (B1, S1, B2, S2) was collected and frozen before 
OT and AVP estimation by the RIA. During in vivo experiment, animals were infused intracerebroventricularly (icv) with triptorelin, at 
a concentration of 10–7 M, and 20 minutes later they were decapitated. The neurohypophysis was dissected from the brain and blood 
plasma samples were collected and frozen for further OT and AVP RIA assays.
Results: The GnRH agonist — triptorelin stimulates both OT and AVP release from isolated H-N system at concentrations of 10–9–10–5 M. 
The strongest effect was displayed by triptorelin at a concentration of 10–7 M. Under the conditions of K+ stimulation, triptorelin affects 
neither OT, nor AVP secretion in vitro. When infused icv, triptorelin, at a concentration of 10–7 M, significantly stimulated both OT and 
AVP secretion into the blood.
Conclusions: Triptorelin may play a role as a neuromodulator contributing to the functional regulation of OT and AVP secretion in the 
rat. (Pol J Endocrinol 2012; 63 (3): 176–182)
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Streszczenie
Wstęp: Wcześniejsze obserwacje sugerowały, że gonadoliberyna (GnRH) może modyfikować uwalnianie hormonów części nerwowej 
przysadki. W praktyce klinicznej zamiast GnRH stosuje się analogi tego hormonu, dlatego celem pracy było zbadanie, czy agonista 
GnRH — tryptorelina zmienia uwalnianie oksytocyny (OT) i wazopresyny (AVP) z układu podwzgórze–część nerwowa przysadki (H-N) 
szczura in vitro oraz in vivo.
Materiał i metody: Po wyosobnieniu z mózgu, układ H-N umieszczano w probówkach zawierających 1 ml płynu Krebsa-Ringera (nKRF). 
Po okresie równoważenia dodawano nKRF zawierający podstawowe (płyn B1) lub zwiększone (56 mM) stężenie jonów K+ (płyn S1), 
a następnie płyny B1 lub S1 zawierające dodatkowo roztwór tryptoreliny w wybranym stężeniu, tj. 10–11–10–5 M (płyny B2 i S2). Po inkubacji 
układu H-N w każdym z roztworów (kolejno: B1, S1, B2, S2) przez 20 min płyn inkubacyjny pobierano i zamrażano do czasu oznaczenia 
w zebranych próbkach zawartości OT i AVP metodą RIA. W doświadczeniu in vivo szczurom, do bocznej komory mózgu (icv), podawano 
roztwór tryptoreliny w stężeniu 10–7 M/L lub jej rozpuszczalnik. Po 20 min od icv infuzji tryptoreliny zwierzęta dekapitowano w celu 
pobrania od nich krwi oraz części nerwowej przysadki. Wyciągi z przysadki i osocze zamrażano do czasu oznaczenia w nich zawartości 
OT i AVP metodą RIA.
Wyniki: Tryptorelina zwiększa podstawowe uwalnianie OT i AVP do płynu inkubacyjnego in vitro w stężeniach 10–9–10–5 M, najsilniejszy 
efekt wywierając w stężeniu 10–7 M. W warunkach pobudzania nadmiarem jonów K+, niezależnie od badanego stężenia tryptoreliny, 
uwalnianie OT i AVP z układu H-N do płynu inkubacyjnego nie różni się istotnie od stwierdzanego w grupie kontrolnej. Infundowana 
icv tryptorelina, w stężeniu 10–7 M, istotnie zwiększa uwalnianie OT i AVP do krwi obwodowej szczura.
Wnioski: Tryptorelina może pełnić u szczura rolę neuromodulatora modyfikującego proces uwalniania OT i AVP. (Endokrynol Pol 2012; 
63 (3): 176–182)
Słowa kluczowe: oksytocyna, wazopresyna, tryptorelina
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Introduction
In mammals, most neurons containing gonadotro-
pin-releasing hormone (GnRH-I) are present in the 
preoptic-hypothalamic region and project to the median 
eminence [1], where the hormone is secreted in a pulsa-
tile pattern to stimulate the biosynthesis and secretion 
of luteinising hormone (LH) and follicle-stimulating 
hormone (FSH) from anterior pituitary gonadotrope 
cells [2]. In the rat and men, neurons which contain 
the GnRH-I have been found to be located close to the 
supraoptic (SON) and paraventricular (PVN) nuclei of 
the hypothalamus [1, 3], where the neurohypophysial 
hormones, i.e. oxytocin (OT) and vasopressin (AVP), are 
synthesised [4]. The GnRH-containing fibres entering 
the neurohypophysis have been observed in the hu-
man pituitary [5], and anatomical synapses between 
GnRH- and AVP-immunoreactive neurons have been 
demonstrated in primates [6]. All the above observations 
suggest that GnRH can influence, at least in part, the 
synthesis and/or secretion of OT and AVP. However, 
very few studies have been performed, either in vivo 
or in vitro, to investigate the effect of GnRH on OT 
and/or AVP secretion from the rat hypothalamo-neu-
rohypophysial system. It has been demonstrated that 
the action of GnRH on oxytocinergic and/or vasopress-
inergic neurons activity depends on the peptide dose, 
the experimental conditions (in vitro or in vivo), and the 
state of water-electrolyte balance [7–12].
GnRH-I is metabolised very fast. The half-life of 
the hormone is very short, i.e. about 2–4 min [13] and 
GnRH mRNA has a rapid rate of decay (t1/2, 5–13 min) 
[14], while its agonistic analogues are more resistant 
to degradation and show stronger receptor binding 
and activation of the receptor than native GnRH-I 
[15, 16]. Therefore, in medical practice, more often than 
GnRH-I itself, its synthetic analogues (i.e. agonists or 
antagonists) are used for the treatment of a wide variety 
of reproductive disorders and hormone-dependent 
malignancies [15, 17, 18]. Such agonists, depending 
on the dose and method and/or duration of treatment 
(i.e. pulsatile versus prolonged application) may have 
a stimulatory or inhibitory influence on gonadotro-
pin synthesis and release. On the other hand, GnRH 
antagonists are able to block GnRH receptors on the 
pituitary and thus inhibit LH and FSH production 
and/or secretion [15, 16].
Triptorelin belongs to one of the commonest GnRH 
agonists used in clinical practice [18–20]. It has been 
shown to have a much longer plasma half-life than 
native GnRH, with an elimination half-life (after single 
peripheral administration) superior to 80 min [21].
The aim of this study was, therefore, to investigate 
the influence of the GnRH agonist — triptorelin on OT 
and AVP secretion from the rat hypothalamo-neurohy-
pophysial system in vitro and in vivo, and whether such 
an effect depends on the concentration of the peptide.
Materials and methods
Animals
Three-month old male Wistar rats (weighing 250–350 g) 
were housed under conditions of constant temperature, 
humidity and lighting (a 12/12 hr light/dark schedule; 
lights on from 6 am). The animals received standard 
pelleted food and had free access to tap water.
Drugs
The gonadotropin-releasing hormone agonist [i.e. 
(D-Trp6)-LHRH acetate salt; Pyr-His-Trp-Ser-Tyr-D-Trp-L
eu-Arg-Pro-Gly-NH2] — triptorelin was purchased from 
BACHEM AG, Bubendorf, Switzerland. The OT (oxy-
tocin synth.) and AVP (vasopressin synth.) for standard 
curve preparation as well as for iodination with 125I, were 
from Peninsula Laboratories Europe Ltd. The anti-VP 
and anti-OT antibodies were raised by dr hab. Monika 
Orłowska-Majdak (Department of Experimental 
Physiology, Chair of Department of Experimental and 
Clinical Physiology, Medical University of Lodz).
Experimental procedure in vitro
Series I. Triptorelin-dependent OT and AVP secretion 
under basal and K+-stimulated conditions was assessed in 
vitro. All animals were decapitated between 10 am 
and 11.30 am. The brain and the pituitary with intact 
pituitary stalk were carefully removed from the skull, 
and a block of hypothalamic tissue was dissected to 
obtain a hypothalamo-neurohypophysial system as 
previously described [22, 23]. After dissection, the 
hypothalamo-neurohypophysial (H-N) explant was im-
mediately placed in a polypropylene tube with 1 ml of 
normal Krebs-Ringer fluid (nKRF) containing: 120 mM 
NaCl, 5 mM KCl, 2.6 mM CaCl2, 1.2 mM KH2PO4, 
0.7 mM MgSO4, 22.5 mM NaHCO3, 10 mM glucose, 
1.0 g/L bovine serum albumin and 0.1 g/L ascorbic acid 
(pH = 7.4–7.5, osmolality = 285–295 mOsm/kg). Tubes 
were placed in a water bath at 37 °C, constantly gassed 
with carbogen (a mixture of 95% O2 and 5% CO2). 
At the beginning of the experiment, the H-N explants 
were equilibrated in nKRF, which was aspirated twice 
and replaced with 1 ml of fresh buffer. After 80 mi nutes 
of such preincubation, necessary for OT and AVP re-
lease stabilisation, the media were discarded and the 
explants were incubated for 20 minutes in 1 ml of nKRF 
alone (control group) or nKRF supplemented with 
an appropriate concentration of triptorelin. Explants 
were incubated successively in: 1 — normal KRF (fluid 
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B1); 2 — modified KRF containing the excess amount 
(56 mM) of K+ (the NaCl concentration was appropri-
ately reduced to maintain medium osmolality) (fluid 
S1); 3 — incubation fluid as B1 (control group) or nKRF 
supplemented with an appropriate concentration of 
triptorelin, i.e. 10–11, 10–10, 10–9, 10–8, 10–7, 10–6 or 10–5 M 
(fluid B2); and 4 — incubation fluid as S1 enriched with 
the same concentration of the studied peptide (fluid S2). 
In between incubation periods S1 and B2, the explants 
were washed for 20 min in nKRF and these samples 
were discarded. After each 20 min incubation period, 
the media (i.e. B1, S1, B2, S2) were collected and samples 
immediately frozen and stored at –20 °C until OT and 
AVP estimation by radioimmunoassay (RIA).
To determine the triptorelin-induced OT and AVP se-
cretion in vitro, the B2/B1 (basal secretion, i.e. without K+ 
stimulation) and S2/S1 (K+-stimulated secretion) ratios 
were calculated for each H-N explant. The results are 
expressed as a B2/B1 or S2/S1 ratio because the amount 
of the hormone released into the medium varies from 
one H-N explant to the other.
Experimental procedure in vivo 
Series II. On the day of the experiment, the rats were 
anaesthetised by an intraperitoneal (ip) injection of 
10% urethane (ethyl carbonate; 1.4 mL/100 g. b. wt) and 
a stainless steel cannula was inserted into the lateral cer-
ebral ventricle (icv) as recommended by Noble et al. [24]. 
Rats were given an icv infusion of 5 mL 0.9% NaCl alone 
or triptorelin at a 10–7 M concentration (the concentra-
tion of the peptide was chosen on the basis of the results 
of the experiment in vitro). The icv infusions were given 
via a polyethylene tube attached to a 10 mL Hamilton 
syringe filled with the appropriate solution. Twenty 
minutes later, the animals were decapitated and the 
neurohypophysis was dissected from the brain. Blood 
plasma samples were collected and frozen for further 
OT and AVP RIA assays, as previously described [25].
The experiments were performed with the consent 
(No 12/ŁB 452/2009 and No 9/ŁB 536/2011) of the Local 
Committee for Animal Care.
Radioimmunoassay of OT and AVP
The AVP and OT concentrations in all samples were de-
termined in duplicate by a specific RIA method described 
previously [23]. Arginine vasopressin and oxytocin were 
iodinated with 125I using the chloramine-T method. The 
final dilution of anti-AVP antibodies was 1:24,000. Cross 
reactivity with oxytocin for anti-AVP antibodies was 
0.016%, with lysine vasopressin — 2.7%, with gonado-
trophin-releasing hormone, thyrotrophin-releasing hor-
mone, leucine enkephalin, angiotensin II and substance 
P — less than 0.002%. The lower limit of detection for the 
assay was 1.56 pg AVP per tube. The intra- and inter-assay 
coefficients of variation were 3.3% and 6.3%, respectively. 
The OT antibody titer was 1:80,000 (final dilution). The 
lower limit of detection was 3.12 pg OT per tube. The 
intra- and inter-assay coefficients of variation were 4.5% 
and 8.3%, respectively.
Statistical evaluation of the results
The data was expressed as means ± S.E.M. and the 
significance between means was evaluated by use of 
the Kruskal-Wallis analysis of variance (ANOVA) by 
ranks for each set of data; as the amount of samples 
per subgroup was small, non-parametric tests were 
chosen. Thereafter, the statistical significance of differ-
ences between the means of two compared subgroups 
was determined by Mann-Whitney ‘U’ test (Statistica, 
StatSoft, Krakow, Poland), estimating p < 0.05 as the 
minimal level of significance.
Results
Series I. The GnRH agonist — triptorelin significantly 
stimulated basal OT (Fig. 1A) and AVP (Fig. 2A) release 
from isolated rat H-N system at concentrations of 10–9– 
–10–5 M. The strongest effect was displayed by triptorelin 
at a concentration of 10–7 M for both OT (8.27 ± 1.98 vs 
1.3 ± 0.26, p < 0.05) and AVP (4.69 ± 1.12 vs 1.11 ± 0.19, 
p < 0.05). Two concentrations of the peptide, i.e. 10–10 M 
(2.0 ± 0.39 vs 1.3 ± 0.26 for OT, p > 0.05 and 1.45 ± 0.4 vs 
1.11 ± 0.19 for AVP, p > 0.05) and 10–11 M (0.96 ± 0.16 vs 
1.3 ± 0.26 for OT, p > 0.05 and 1.06 ± 0.26 vs 1.11 ± 0.19 
for AVP, p > 0.05), remained inactive in modifying these 
hormones secretion in vitro. Under the conditions of K+ 
stimulation, triptorelin affected neither OT nor AVP 
secretion in vitro (Figs. 1B and 2B).
Series II. The GnRH agonist, at a concentration of 
10–7 M, significantly stimulated both OT and AVP se-
cretion from the rat neurohypophysis into the blood 
(Figs. 3A and 3B). Namely, triptorelin was able to dimin-
ish both OT (911.16 ± 84.75 vs 1,594.67 ± 177.9, p < 0.01) 
and AVP (689.77 ± 75.0 vs 1,360.42 ± 110.0, p < 0.01) 
content in the neurohypophysis (Fig. 3A), while blood 
plasma OT (25.43 ± 6.23 vs 8.3 ± 0.92, p < 0.01) and AVP 
(16.3 ± 2.5 vs 8.46 ± 0.93, p < 0.01) concentrations were 
significantly higher in rats infused icv with triptorelin 
than in control animals (Fig. 3B).
Discussion
The oxytocinergic and vasopressinergic neurons 
function is altered by several factors, e.g. parturition, 
suckling, hypovolaemia, hyperosmotic stimulation, 
angiotensin II or stress [7–10, 25–30] as well as by nu-
merous peptides [23, 26, 31–33], which play a role as 
neuromediators and/or neuromodulators in the hypo-
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thalamus and other central nervous system regions. Re-
sults from the present study show, for the first time, that 
the GnRH agonist – triptorelin is a potent stimulus (at 
concentrations of 10–9–10–5 M) for OT and AVP output 
from isolated rat hypothalamo-neurohypophysial 
complex. The most active in this respect concentration 
of the peptide is 10–7 M, which is in accordance with the 
effect of the other GnRH agonist — histrelin [11–12]. We 
have also shown that centrally administered triptorelin 
(at a concentration of 10–7 M) may be involved in the 
mechanisms controlling the activity of oxytocinergic 
and vasopressinergic neurons, acting probably through 
a specific GnRH-I receptor in the hypothalamus. Such 
a suggestion is based on the fact that in the rat, the 
Figure 1. The effect of gonadotropin-releasing hormone (GnRH) agonist — triptorelin, at concentrations of 10–11–10–5 M, on basal (A) 
and K+-stimulated (B) oxytocin (OT) release from the rat hypothalamo–neurohypophysial complex in vitro. Each bar represents mean 
± SEM; number of samples per group (n) = 8–9, *p < 0.05 — significantly different vs control
Rycina 1. Wpływ agonisty gonadoliberyny — tryptoreliny, w stężeniach 10–11–10–5 M, na podstawowe (A) i pobudzane nadmiarem 
jonów K+ (B) uwalnianie oksytocyny (OT) z układu podwzgórze–część nerwowa przysadki szczura in vitro. Wyniki przedstawiają 
średnią ± SEM; liczba próbek w grupie (n) = 8–9; *p < 0,05 — różnica istotna statystycznie względem kontroli
Figure 2. The effect of gonadotropin-releasing hormone (GnRH) agonist — triptorelin, at concentrations of 10–11–10–5 M, on basal (A) 
and K+-stimulated (B) vasopressin (AVP) release from the rat hypothalamo–neurohypophysial complex in vitro. Each bar represents 
mean ± SEM; number of samples per group (n) = 9; *p < 0.05 — significantly different vs control
Rycina 2. Wpływ agonisty gonadoliberyny — tryptoreliny, w stężeniach 10–11–10–5 M, na podstawowe (A) i pobudzane nadmiarem 
jonów K+ (B) uwalnianie wazopresyny (AVP) z układu podwzgórze–część nerwowa przysadki szczura in vitro. Wyniki przedstawiają 
średnią ± SEM; liczba próbek w grupie (n) = 9; *p < 0,05 — różnica istotna statystycznie względem kontroli
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GnRH-immunoreactive fibres are present in the hypo-
thalamus and median eminence, but they do not project 
into the posterior pituitary [34].
The GnRH agonist employed in our present study, 
i.e. triptorelin, is one of the commonest GnRH ago-
nists [17–20], and is approximately 15 to 20 times more 
potent than native GnRH-I [15, 35]. It has been found 
to stimulate LH release from the rat pituitary in vitro 
[16]. Moreover, in adult rats icv administration of 10, 
100 and 1,000 ng/animal of triptorelin exerts signifi-
cant actions on the central nervous system, as early as 
20 minutes after the injection [36]. Under present 
experimental conditions, 20 min incubation in vitro 
of the hypothalamo-neurohypophysial explant in the 
medium containing triptorelin (and similarly in vivo, 
20 min interval between icv infusion of triptorelin and 
decapitation) should imitate the effect of one pulse of 
natural GnRH on neurohypophysial hormones secre-
tion at the physiological situation.
It is well established that K+-induced depolarisation 
stimulates both cell bodies in the magnocellular nuclei 
and axon terminals in the neurohypophysis [22, 31]. 
Under present in vitro conditions, triptorelin failed to 
modify the K+-evoked release of the neurohypophysial 
hormones. The possibility is that the increase in the 
hormone’s release as evoked by K+ stimulation under S1 
period attenuated the responsiveness of both oxytocin-
ergic and vasopressinergic neurones to GnRH agonist 
during the successive incubation period S2. However, 
when the effect of LHRH on K+-evoked release of AVP 
and OT was studied in vitro, the hormone at a dose of 
40 nM displayed no significant influence on OT [8], but 
reduced AVP [7] secretion from the hypothalamo-neu-
rohypophysial explants obtained from euhydrated rats.
Mechanisms by which GnRH agonist could af-
fect OT and/or AVP release are not well understood. 
In the rat, only one of the two receptors present in 
mammals, i.e. GnRH-I receptor, is active [37]. The 
GnRH-I receptors are localised mainly in the hypo-
thalamus (its mediobasal and ventromedial part) and 
anterior pituitary [38, 39], but not in the neurohypo-
physis. Since for the present in vitro experiment we 
used the whole hypothalamo-neurohypophysial com-
plex (with direct axonal projection from the SON and 
PVN to the neurohypophysis), instead of the posterior 
pituitary separated from the brain, it is very probable 
that GnRH agonist — triptorelin was able to increase 
OT and AVP release acting at the hypothalamic level 
through GnRH-I receptor (both in vitro and in vivo). 
GnRH agonist could also modify the SON and/or PVN 
neurons activity indirectly via suprachiasmatic nucleus 
(SCN); the explant employed in the present in vitro 
experiments contained, apart from SON and PVN, also 
SCN and other anterior hypothalamic nuclei [22]. An 
anatomical basis for such a hypothesis is the existence 
of synaptic contacts between GnRH-containing neurons 
Figure 3. The effect of icv infusion of gonadotropin-releasing hormone (GnRH) agonist — triptorelin, at a concentration of 10–7 M, on the 
neurohypophysial (NH) content (A) and blood plasma concentrations (B) of oxytocin (OT) and vasopressin (AVP). Each bar represents 
mean ± SEM; number of animals per group (n) = 8; *p < 0.01 — significantly different vs control (0.9% NaCl)
Rycina 3. Wpływ dokomorowej (icv) infuzji agonisty gonadoliberyny — tryptoreliny, w stężeniu 10–7 M, na zawartość oksytocyny (OT) 
i wazopresyny (AVP) w części nerwowej przysadki (A) oraz stężenie OT i AVP we krwi obwodowej (B) szczura. Wyniki przedstawiają 
średnią ± SEM; liczba zwierząt w grupie (n) = 8; *p < 0,01 — różnica istotna statystycznie względem kontroli (0,9% NaCl)
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of the preoptic area (the region that contains the major-
ity of the GnRH-synthesising neurons in the rat) and 
neurons in the SCN [40], which have direct neuronal 
projection to PVN [41] and SON [42]. Some of the SCN 
neurons could, therefore, integrate the afferent signals 
from other hypothalamic nuclei and/or different brain 
areas (both under in vitro and in vivo conditions) and 
thereafter transmit them directly to oxytocinergic and 
vasopressinergic neurons in the SON and/or PVN. It 
has been found that the SCN neurons can influence 
function of the PVN and SON neurons by releasing 
from their axonal endings either excitatory (glutamate) 
or inhibitory (GABA) amino acids [41, 42], which have 
been shown to increase or decrease plasma OT and/or 
AVP level, respectively [26]. Another possibility involves 
indirect projection from the SCN to the SON through 
the GnRH-ergic cells in the preoptic area [1, 43]. Such 
a direct neuronal pathway from the SCN to the preoptic 
area has been found to transmit, in the female rat, the 
circadian rhythm from the SCN to the GnRH neurons 
via AVP-containing fibres [44].
The influence of GnRH agonist on OT and AVP 
secretion can also be mediated by some neuromedia-
tors/neuromodulators and neuroactive agents (present 
in the hypothalamus and/or posterior pituitary) such 
as dopamine, arachidonic acid and its metabolites, 
glutamate, GABA, nitric oxide, opioid peptides, neuro-
steroids and oestrogens [33, 36, 45–48]. Quite recently, 
triptorelin was found to induce nitric oxide synthase 
type 1 (NOS1) expression in female rat pituitary cells, 
both in vitro and in vivo [49].
All the above mentioned factors are involved in 
modifying OT and AVP release from the rat hypo-
thalamo-neurohypophysial system [26, 31, 33, 50, 51] 
and a certain combination of these agents may be crucial 
for the mechanisms by which oxytocinergic and vaso-
pressinergic neurons are influenced by GnRH and/or 
its agonists.
Conclusions
The GnRH agonist — triptorelin, acting probably 
through a specific GnRH receptor in the hypothalamus, 
may play a role as a neuromodulator contributing to the 
regulation of oxytocinergic and vasopressinergic neu-
rons secretory activity in the rat, and thus may indirectly 
influence water balance of the organism and several 
other processes, which are regulated by OT and/or AVP.
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